GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,750.00p
   
  • Change Today:
      14.50p
  • 52 Week High: 2,208.00
  • 52 Week Low: 1,620.00
  • Currency: UK Pounds
  • Shares Issued: 4,045.43m
  • Volume: 6,854,112
  • Market Cap: £70,795m
  • RiskGrade: 129
  • Beta: 0.00

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Luke Miels
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Vishal Sikka
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Hal Barron , Wendy Becker , Jeannie Lee , Gavin Screaton, Roy Jakobs

Contact Details

Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com/en-gb/

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,750.00p
Change Today 14.50p
% Change 0.84 %
52 Week High 2,208.00
52 Week Low 1,620.00
Volume 6,854,112
Shares Issued 4,045.43m
Market Cap £70,795m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
76.23% below the market average76.23% below the market average76.23% below the market average76.23% below the market average76.23% below the market average
36.84% below the sector average36.84% below the sector average36.84% below the sector average36.84% below the sector average36.84% below the sector average
Price Trend
75.14% above the market average75.14% above the market average75.14% above the market average75.14% above the market average75.14% above the market average
72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average
Income
23.24% above the market average23.24% above the market average23.24% above the market average23.24% above the market average23.24% above the market average
Sector averageSector averageSector averageSector averageSector average
Growth
39.83% above the market average39.83% above the market average39.83% above the market average39.83% above the market average39.83% above the market average
28.57% below the sector average28.57% below the sector average28.57% below the sector average28.57% below the sector average28.57% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 12
Sell 2
Strong Sell 0
Total 21
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 13-Aug-26 14-May-26
Paid 08-Oct-26 09-Jul-26
Amount 17.00p 17.00p

Trades for 09-Oct-2026

Time Volume / Share Price
17:03 301,000 @ 1,752.00p
16:58 301,000 @ 1,752.00p
16:39 514 @ 1,750.00p
16:39 110 @ 1,750.00p
16:39 4 @ 1,750.00p

GSK Key Personnel

CEO Luke Miels

Top of Page